Biotechnology News and Research

RSS

Donald Danforth Center receives $11.9M funding for Virus Resistant Cassava for Africa project

The Donald Danforth Plant Science Center announced today that it has received additional funding totaling $11.9 million for the Virus Resistant Cassava for Africa (VIRCA) project to advance its work to improve the health and wellbeing of farmers, their families, and other consumers of cassava living in Sub Saharan Africa.

8 Sep 2011

Biochemists reveal interaction between tumor suppressor protein and chaperone

Every cell has thousands of proteins whose activity and lifetime must be regulated to control the cellular life cycle from cell division to cell death. The heat shock protein Hsp90 plays a key role in this process. It is a so-called chaperone, a quality controller, as it were. It monitors and controls the quality and activity of many important signal proteins and helps them take on the right form. When the cell is exposed to high stress levels from heat or a lack of oxygen, Hsp90 is produced in larger quantities to shield its partner proteins from damage.

8 Sep 2011

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Teva Pharmaceutical Industries Ltd. and Alcobra Ltd. announced today top-line results from a six week, randomized, placebo-controlled, Phase II multi-center study designed to assess the safety and efficacy of MG01CI in adults with attention deficit hyperactivity disorder (ADHD).

7 Sep 2011

Simulations Plus preliminary fourth quarter revenues increase 6.9% to $1.426 million

Simulations Plus, Inc., a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its fourth fiscal quarter of fiscal year 2011, ended August 31, 2011 (4QFY11), and for the entire fiscal year 2011 (FY11).

7 Sep 2011

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.

7 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Labcyte Inc., a leader in miniaturization technologies for liquid handling, announced today that Thermo Fisher Scientific, the world leader in serving science, is offering the option for customers to receive siRNA (small-interfering RNA) reagent libraries in Labcyte Echo qualified source plates.

From Thermo Fisher Scientific Inc. 7 Sep 2011

Study on effects of adult stem cell treatments in patients with Hereditary Ataxia

The Journal of Translational Medicine reports on a new study in which 30 patients with Hereditary Ataxia showed statistically significant improvements in functionality and quality of life after being treated with a combination of cord blood-derived stem cell treatments and physical therapy.

7 Sep 2011

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

Discovery Labs, Inc. today announced that, on September 2, 2011, it submitted its Complete Response to the 2009 Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for SURFAXIN(lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants.

6 Sep 2011

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today it will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio.

6 Sep 2011

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

QIAGEN today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

From QIAGEN Manchester Limited 6 Sep 2011

Researchers discover novel way to increase amounts of antibiotics

A novel way of increasing the amounts of antibiotics produced by bacteria has been discovered that could markedly improve the yields of these important compounds in commercial production. It could also be valuable in helping to discover new compounds. With the ever-growing threat from antibiotic resistance, these tools will be very useful in ensuring that we have enough of these useful compounds in the future.

5 Sep 2011

DiaGenic allots options to employees

According to the resolution by the Annual General Meeting on 23 May 2011, the Board of Directors in DiaGenic ASA today allotted options to DiaGenic employees. The share options have strike price of NOK 6.00 per share, which is set based on last week weighted share price + 10%. The options have life of 4 years and can be exercised after 3 years.

5 Sep 2011

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

Using a strategy based on treating cancer cells that carry a specific genetic signature - hyper-expression of the protein Myc - with therapy that affects the stability of the cell's DNA, more effective results can be achieved.

5 Sep 2011

UCF, UF receive $5.5 million NIH grant for hemophilia research

At a time when research funding is hard to come by, a University of Central Florida and University of Florida partnership has landed almost $5.5 million in National Institutes of Health highly competitive grants for hemophilia research.

3 Sep 2011

Nature journal publishes Metabolon's genome wide association study

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced the publication of "Human Metabolic Individuality in Biomedical and Pharmaceutical Research" in the journal Nature.

3 Sep 2011

PTC restructures collaboration with Genzyme

PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original agreement, PTC held commercial rights for the U.S. and Canada and Genzyme held commercial rights in all other countries.

2 Sep 2011

AmerisourceBergen completes acquisition of Premier Source

AmerisourceBergen Corporation today announced that it has completed the acquisition of Premier Source, a privately held company that provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic, and biotechnology manufacturers, as well as other health services companies.

2 Sep 2011

SuperGen is now Astex Pharmaceuticals

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it anticipates that it will begin operating under the name Astex Pharmaceuticals, Inc. on September 12, 2011.

2 Sep 2011

Special journal edition chronicles 3-D structures of important antibacterial, bioterrorist targets

The September issue of the online scientific journal Acta Crystallographica: Structural Biology and Crystallization Communications (Acta Cryst F) will consist entirely of work done at the Seattle Structural Genomics Center for Infectious Disease (SSGCID), a consortium of researchers from Seattle BioMed, Emerald BioStructures, the University of Washington and Pacific Northwest National Laboratory.

2 Sep 2011

Biotechnology News and Research

Donald Danforth Center receives $11.9M funding for Virus Resistant Cassava for Africa project

Biochemists reveal interaction between tumor suppressor protein and chaperone

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Simulations Plus preliminary fourth quarter revenues increase 6.9% to $1.426 million

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Study on effects of adult stem cell treatments in patients with Hereditary Ataxia

Discovery Labs files Complete Response to FDA for SURFAXIN to treat RDS in premature infants

NanoLogix to move R&D operations from Cincinnati to its headquarters in Hubbard

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

Researchers discover novel way to increase amounts of antibiotics

DiaGenic allots options to employees

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

UCF, UF receive $5.5 million NIH grant for hemophilia research

Nature journal publishes Metabolon's genome wide association study

PTC restructures collaboration with Genzyme

AmerisourceBergen completes acquisition of Premier Source

SuperGen is now Astex Pharmaceuticals

Special journal edition chronicles 3-D structures of important antibacterial, bioterrorist targets

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News